Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Lamivudine Penetration in Retinal Detachment Surgery
NCT06056596Phase 1Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Jan 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rhegmatogenous retinal detachment (RRD) comparing Lamivudine with Placebo (2 arms). Primary endpoints: Plasma concentration of lamivudine after oral administration and Intra-ocular concentration of lamivudine after oral administration. Started Jan 2024; status: terminated.
02
Drugs
lamivudine
03
Conditions
rhegmatogenous retinal detachment (RRD)
Beyond the preview
Go deeper on NCT06056596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056596.